Thorsten Nowak
About Thorsten Nowak
Thorsten Nowak serves as the Vice President of Medicinal Chemistry at Exscientia, where he leads a team focused on utilizing AI and machine learning to enhance drug design. He has extensive experience in medicinal chemistry, having held various leadership roles at AstraZeneca and C4X Discovery Ltd.
Work at Exscientia
Thorsten Nowak serves as the Vice President of Medicinal Chemistry at Exscientia, a position he has held since 2020. In this role, he leads a team of scientists focused on integrating artificial intelligence and machine learning into drug design processes. His responsibilities include exploring innovative approaches to enhance the development of technologies and platforms for drug design. Under his leadership, the team aims to transform traditional drug design methodologies by applying advanced computational methods.
Previous Experience in Medicinal Chemistry
Before joining Exscientia, Thorsten Nowak held various positions in medicinal chemistry. He worked at Lead Discovery Center GmbH as the Medicinal Chemistry Group Leader from 2019 to 2020. Prior to that, he spent 12 years at AstraZeneca, where he progressed from a Medicinal Chemist to a Team Leader and Associate Principal Scientist. His career also includes a role as Senior Medicinal Chemist at C4X Discovery Ltd from 2012 to 2013, and later as VP of Structural Design & Medicinal Chemistry at the same company from 2016 to 2019.
Educational Background
Thorsten Nowak has a strong academic foundation in chemistry. He studied at the University of Düsseldorf, where he earned a Diplomchemiker degree from 1985 to 1987. He then attended Ruprecht-Karls-Universität Heidelberg, obtaining a Diploma in Chemistry from 1989 to 1993. His education culminated with a Ph.D. in Organic Chemistry from the University of Cambridge, which he completed from 1993 to 1996.
Leadership in Drug Design
At Exscientia, Thorsten Nowak plays a pivotal role in leading a team that leverages artificial intelligence and machine learning to innovate drug design processes. His contributions focus on the application of high-performance computational methods to enhance drug design. This leadership position underscores his commitment to advancing the field of medicinal chemistry through modern technological approaches.